Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

#2161

Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.

Aim(s): Surgical resection, ablation, embolization, or radiation, can control discrete sites of progression, allowing patients to continue their existing therapy, and sparing them toxicities of a new systemic treatment.

Materials and methods: We reviewed records to identify patients seen between 1/2014 and 5/2017 with metastatic GEP-NETs who underwent local treatment for focal progression. Patients undergoing lobar HAE or cytoreductive hepatic surgery were not included. The primary endpoint was time to new systemic therapy. Secondary endpoints included time to any additional intervention, PFS, and side effects of treatment.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Strosberg J

Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,

Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,